Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 12.98 Million USD | -74.54% |
| 2022 | 51.02 Million USD | -38.17% |
| 2021 | 82.52 Million USD | -34.64% |
| 2020 | 126.26 Million USD | 25.66% |
| 2019 | 100.47 Million USD | 495.59% |
| 2018 | 16.87 Million USD | 40.97% |
| 2017 | 11.96 Million USD | 38.54% |
| 2016 | 8.63 Million USD | -43.59% |
| 2015 | 15.31 Million USD | -43.88% |
| 2014 | 27.28 Million USD | -4.18% |
| 2013 | 28.47 Million USD | 2735.74% |
| 2012 | 1 Million USD | 54.91% |
| 2011 | 648.24 Thousand USD | -68.4% |
| 2010 | 2.05 Million USD | -6.01% |
| 2009 | 2.18 Million USD | -68.39% |
| 2008 | 6.9 Million USD | -40.84% |
| 2007 | 11.67 Million USD | -19.32% |
| 2006 | 14.46 Million USD | 39.0% |
| 2005 | 10.4 Million USD | -52.62% |
| 2004 | 21.96 Million USD | -13.06% |
| 2003 | 25.26 Million USD | 1.24% |
| 2002 | 24.95 Million USD | -19.83% |
| 2001 | 31.13 Million USD | -22.56% |
| 2000 | 40.19 Million USD | -16.76% |
| 1999 | 48.29 Million USD | 2125.33% |
| 1998 | 2.17 Million USD | -46.42% |
| 1997 | 4.05 Million USD | -47.34% |
| 1996 | 7.69 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 12.79 Million USD | -1.49% |
| 2024 Q2 | 10.94 Million USD | -14.43% |
| 2023 Q3 | 20.87 Million USD | -21.44% |
| 2023 Q1 | 39.33 Million USD | -22.92% |
| 2023 Q2 | 26.57 Million USD | -32.43% |
| 2023 Q4 | 12.98 Million USD | -37.78% |
| 2023 FY | 12.98 Million USD | -74.54% |
| 2022 Q2 | 64.8 Million USD | -10.74% |
| 2022 Q1 | 72.6 Million USD | -12.02% |
| 2022 Q3 | 57.04 Million USD | -11.97% |
| 2022 Q4 | 51.02 Million USD | -10.55% |
| 2022 FY | 51.02 Million USD | -38.17% |
| 2021 Q2 | 106.21 Million USD | -7.8% |
| 2021 Q3 | 97.19 Million USD | -8.49% |
| 2021 Q4 | 82.52 Million USD | -15.1% |
| 2021 FY | 82.52 Million USD | -34.64% |
| 2021 Q1 | 115.19 Million USD | -8.77% |
| 2020 Q4 | 126.26 Million USD | -6.65% |
| 2020 Q3 | 135.25 Million USD | 58.53% |
| 2020 Q2 | 85.31 Million USD | -7.82% |
| 2020 Q1 | 92.55 Million USD | -7.88% |
| 2020 FY | 126.26 Million USD | 25.66% |
| 2019 Q3 | 32.46 Million USD | -15.0% |
| 2019 Q1 | 19.72 Million USD | 16.91% |
| 2019 Q4 | 100.47 Million USD | 209.54% |
| 2019 FY | 100.47 Million USD | 495.59% |
| 2019 Q2 | 38.19 Million USD | 93.63% |
| 2018 Q4 | 16.87 Million USD | 3.53% |
| 2018 Q2 | 19.28 Million USD | 15.68% |
| 2018 FY | 16.87 Million USD | 40.97% |
| 2018 Q1 | 16.67 Million USD | 39.33% |
| 2018 Q3 | 16.29 Million USD | -15.52% |
| 2017 Q4 | 11.96 Million USD | 6.74% |
| 2017 Q3 | 11.21 Million USD | -0.72% |
| 2017 Q2 | 11.29 Million USD | 18.81% |
| 2017 Q1 | 9.5 Million USD | 10.04% |
| 2017 FY | 11.96 Million USD | 38.54% |
| 2016 Q4 | 8.63 Million USD | 2.24% |
| 2016 Q1 | 12.49 Million USD | -18.43% |
| 2016 Q2 | 10.45 Million USD | -16.26% |
| 2016 FY | 8.63 Million USD | -43.59% |
| 2016 Q3 | 8.44 Million USD | -19.22% |
| 2015 Q4 | 15.31 Million USD | -15.54% |
| 2015 FY | 15.31 Million USD | -43.88% |
| 2015 Q1 | 23.76 Million USD | 86998.06% |
| 2015 Q2 | 21.3 Million USD | -10.36% |
| 2015 Q3 | 18.13 Million USD | -14.89% |
| 2014 Q2 | 28.47 Million USD | 309.15% |
| 2014 Q4 | 27.28 Thousand USD | -99.91% |
| 2014 Q1 | 6.95 Million USD | 229.14% |
| 2014 FY | 27.28 Million USD | -4.18% |
| 2014 Q3 | 30.26 Million USD | 6.29% |
| 2013 Q3 | 930.56 Thousand USD | -7.33% |
| 2013 Q4 | 2.11 Million USD | 127.24% |
| 2013 Q1 | 1.79 Million USD | -44.68% |
| 2013 Q2 | 1 Million USD | -43.95% |
| 2013 FY | 28.47 Million USD | 2735.74% |
| 2012 Q3 | 4.63 Million USD | 615.36% |
| 2012 Q1 | 508.93 Thousand USD | -62.17% |
| 2012 Q4 | 3.23 Million USD | -30.16% |
| 2012 FY | 1 Million USD | 54.91% |
| 2012 Q2 | 648.24 Thousand USD | 27.37% |
| 2011 Q3 | 2.32 Million USD | 13.28% |
| 2011 FY | 648.24 Thousand USD | -68.4% |
| 2011 Q4 | 1.34 Million USD | -42.12% |
| 2011 Q2 | 2.05 Million USD | -29.33% |
| 2011 Q1 | 2.9 Million USD | -5.14% |
| 2010 Q1 | 2.46 Million USD | -40.79% |
| 2010 Q2 | 2.18 Million USD | -11.42% |
| 2010 Q4 | 3.06 Million USD | 89.22% |
| 2010 Q3 | 1.61 Million USD | -25.9% |
| 2010 FY | 2.05 Million USD | -6.01% |
| 2009 Q2 | 6.9 Million USD | -0.85% |
| 2009 Q3 | 2.85 Million USD | -58.64% |
| 2009 Q4 | 4.16 Million USD | 45.73% |
| 2009 FY | 2.18 Million USD | -68.39% |
| 2009 Q1 | 6.96 Million USD | -19.83% |
| 2008 Q3 | 12.19 Million USD | 4.44% |
| 2008 FY | 6.9 Million USD | -40.84% |
| 2008 Q4 | 8.68 Million USD | -28.74% |
| 2008 Q1 | 14.57 Million USD | -14.26% |
| 2008 Q2 | 11.67 Million USD | -19.89% |
| 2007 FY | 11.67 Million USD | -19.32% |
| 2007 Q1 | 13.65 Million USD | -13.81% |
| 2007 Q3 | 18.42 Million USD | 27.34% |
| 2007 Q4 | 16.99 Million USD | -7.77% |
| 2007 Q2 | 14.46 Million USD | 6.0% |
| 2006 Q4 | 15.83 Million USD | -16.52% |
| 2006 Q3 | 18.97 Million USD | 82.25% |
| 2006 Q2 | 10.4 Million USD | -15.77% |
| 2006 FY | 14.46 Million USD | 39.0% |
| 2006 Q1 | 12.35 Million USD | -23.56% |
| 2005 Q4 | 16.16 Million USD | -14.44% |
| 2005 Q3 | 18.89 Million USD | -13.99% |
| 2005 Q2 | 21.96 Million USD | 0.93% |
| 2005 Q1 | 21.76 Million USD | -3.54% |
| 2005 FY | 10.4 Million USD | -52.62% |
| 2004 FY | 21.96 Million USD | -13.06% |
| 2004 Q3 | 21.46 Million USD | -15.03% |
| 2004 Q2 | 25.26 Million USD | -23.82% |
| 2004 Q1 | 33.16 Million USD | -14.93% |
| 2004 Q4 | 22.56 Million USD | 5.1% |
| 2003 Q1 | 24.79 Million USD | -5.69% |
| 2003 FY | 25.26 Million USD | 1.24% |
| 2003 Q4 | 38.98 Million USD | -6.15% |
| 2003 Q3 | 41.54 Million USD | 66.45% |
| 2003 Q2 | 24.95 Million USD | 0.67% |
| 2002 Q4 | 26.28 Million USD | -7.7% |
| 2002 Q1 | 32.01 Million USD | -5.51% |
| 2002 FY | 24.95 Million USD | -19.83% |
| 2002 Q2 | 31.13 Million USD | -2.77% |
| 2002 Q3 | 28.48 Million USD | -8.51% |
| 2001 Q4 | 33.88 Million USD | -9.4% |
| 2001 FY | 31.13 Million USD | -22.56% |
| 2001 Q1 | 41.42 Million USD | -3.66% |
| 2001 Q2 | 40.19 Million USD | -2.97% |
| 2001 Q3 | 37.4 Million USD | -6.96% |
| 2000 Q4 | 43 Million USD | -7.62% |
| 2000 Q2 | 48.29 Million USD | 132.82% |
| 2000 Q3 | 46.54 Million USD | -3.62% |
| 2000 Q1 | 20.74 Million USD | 17.94% |
| 2000 FY | 40.19 Million USD | -16.76% |
| 1999 Q1 | 2.91 Million USD | 17.9% |
| 1999 Q3 | 1.87 Million USD | -13.67% |
| 1999 FY | 48.29 Million USD | 2125.33% |
| 1999 Q4 | 17.58 Million USD | 838.83% |
| 1999 Q2 | 2.17 Million USD | -25.6% |
| 1998 FY | 2.17 Million USD | -46.42% |
| 1998 Q4 | 2.47 Million USD | -18.54% |
| 1998 Q1 | 4.28 Million USD | -24.7% |
| 1998 Q2 | 4.05 Million USD | -5.5% |
| 1998 Q3 | 3.03 Million USD | -25.02% |
| 1997 Q3 | 6.62 Million USD | 0.0% |
| 1997 FY | 4.05 Million USD | -47.34% |
| 1997 Q4 | 5.69 Million USD | -14.06% |
| 1996 FY | 7.69 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -771.509% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | 51.394% |
| Helix BioPharma Corp. | 1.48 Million CAD | -772.33% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 63.568% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | 32.116% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 70.678% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 66.54% |
| Sernova Corp. | 22.1 Million CAD | 41.244% |